Showing results (171-180 of 216) with videos related to

Sort By:
Pageof 22
Journal for Immunotherapy of Cancer|July 13, 2026
BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for <i>EGFR</i>-mutated advanced non-small-cell lung cancer: a phase 1b trialYuxiang Ma, Chunjiao Wu, Yan-Qiu Zhao, et al.
Frontiers in Immunology|November 21, 2024
Association of artificial intelligence-based immunoscore with the efficacy of chemoimmunotherapy in patients with advanced non-squamous non-small cell lung cancer: a multicentre retrospective studyJiaqing Liu, Dongchen Sun, Shuoyu Xu, et al.
Cell Reports. Medicine|February 8, 2024
Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphomaYuxiang Ma, Fan Luo, Yang Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 5, 2024
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysisShen Zhao, Yuxiang Ma, Lianke Liu, et al.
Oncotargets and Therapy|November 9, 2013
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLCXuan Wu, Wenhua Liang, Xue Hou, et al.
Acta Pharmaceutica Sinica. B|September 30, 2022
<i>FOXO3</i> mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagyShaoxing Guan, Xi Chen, Youhao Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2024
Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non-Small Cell Lung CancerShaoxing Guan, Xi Chen, Yuru Wei, et al.
Thoracic Cancer|April 19, 2022
A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatmentYongluo Jiang, Yixing Wang, Sha Fu, et al.
Clinical & Translational Immunology|October 19, 2020
Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancerHeping Liu, Yuxiang Ma, Chaopin Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapyLi-Na He, Tao Chen, Sha Fu, et al.
Pageof 22